Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel compounds, pharmaceutically acceptable salts as vanilloid receptor antagonist and pharmaceutical composition comprising the compounds

A compound and pharmaceutical technology, applied in the field of pharmaceutical compositions containing these compounds, can solve problems such as nerve function damage and nerve cell death

Active Publication Date: 2013-08-21
AMOREPACIFIC CORP
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, primary cultures of afferent sensory neurons were treated with TRPV1 agonist capsaicin, etc., resulting in impairment of nerve function and death of nerve cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel compounds, pharmaceutically acceptable salts as vanilloid receptor antagonist and pharmaceutical composition comprising the compounds
  • Novel compounds, pharmaceutically acceptable salts as vanilloid receptor antagonist and pharmaceutical composition comprising the compounds
  • Novel compounds, pharmaceutically acceptable salts as vanilloid receptor antagonist and pharmaceutical composition comprising the compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0915] Example 1: 3-(6-tert-butyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-benzyl)-acrylamide

[0916]

[0917] Step 1: Synthesis of 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid

[0918] To a solution of 6-tert-butyl-pyridine-3-carbaldehyde (1.34 g, 8.75 mmol) in toluene prepared according to a known method was added methyl (triphenylphosphino)acetate (2.93 g) to give The mixture was heated at 90°C for 3 hours. The reaction mixture was diluted with EtOAc, then washed with water and brine. There are several layers in anhydrous MgSO 4 Dry over and concentrate under reduced pressure. The resulting residue was purified by column chromatography (Hex / EtOAc=4 / 1) to give the ester product (1.56 g, 81%). The resulting ester was dissolved in 1,4-dioxane, treated with water and KOH, stirred, then heated at reflux for 18 hours. The reaction mixture was cooled to room temperature, diluted with water, and washed with ether. The aqueous phase was acidified with 1N HCl, followe...

Embodiment 2

[0924] Example 2: 3-(6-tert-butyl-pyridin-3-yl)-N-(3-chloro-4-methanesulfonylamino-benzyl)-acrylamide

[0925]

[0926] N-(4-Aminomethyl-2-chloro-phenyl)-methanesulfonamide, HCl salt (100mg, 0.35mmol) and 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid (70mg) The reaction afforded 3-(6-tert-butyl-pyridin-3-yl)-N-(3-chloro-4-methanesulfonylamino-benzyl after column chromatography purification (Hex / EtOAc=1 / 2) )-acrylamide (110 mg, 74%).

[0927] 1 H NMR (300MHz, CDCl 3 ): δ8.66 (d, 1H, J = 2.1Hz), 7.74 (dd, 1H, J = 2.1 and 8.1Hz), 7.64 (d, 1H, J = 15.6Hz), 7.57 (d, 1H, J = 8.7Hz), 7.41(d, 1H, J=2.1Hz), 7.36(d, 1H, J=8.1Hz), 7.24(dd, 1H, J=2.1and 8.7Hz), 6.82(s, 1H), 6.48 (d, 1H, J=15.6Hz), 6.42(t, 1H), 4.53(d, 2H, J=6.0Hz), 3.00(s, 3H), 1.37(s, 9H)

[0928] ESI[M+H] + : 422.2.

Embodiment 3

[0929] Example 3: 3-(6-tert-butyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide

[0930]

[0931] N-(4-Aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide, HCl salt (70mg, 0.25mmol) and 3-(6-tert-butyl-pyridin-3-yl) - reaction of acrylic acid (52 mg) to give 3-(6-tert-butyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro after purification by column chromatography (Hex / EtOAc=1 / 2) - 4-Methanesulfonylamino-benzyl)-acrylamide (63 mg, 64%).

[0932] 1 H NMR (300MHz CDCl 3 ): δ8.71 (d, 1H, J = 2.4Hz), 7.76 (dd, 1H, J = 2.4 and 8.4Hz), 7.63 (d, 1H, J = 16.0Hz), 7.39 (d, 1H, J = 8.4Hz), 7.28(s, 1H), 7.16(dd, 1H, J=2.1 and 11.0Hz), 6.64(s, 1H), 6.52(d, 1H, J=16.0Hz), 6.47(t, 1H) , 4.51(d, 2H, J=6.0Hz), 3.45(s, 1H), 3.24(s, 3H), 1.38(s, 9H)

[0933] ESI[M+H] + : 430.1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This present invention relates to novel compounds, of the formula (I), isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1;VR1;TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic / allergic / inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis and pancreatitis.

Description

technical field [0001] The present invention relates to novel compounds as TRPV1 antagonists, isomers or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising these compounds. Background technique [0002] Described vanillic acid receptor-1 (VR1, or transient receptor potential vanillic acid-1, TRPV1) is a kind of excitant component in capsicum---capsaicin (8-methyl-N-vanillyl-6-nonyl Enamide) receptors. The molecular cloning of TRPV1 was reported in 1997 (Caterina et al., 1997, Nature, 389, pp816-824), which belongs to the TRP channel family of non-selective cation channels. TRPV1 is activated or sensitized by stimuli such as capsaicin, resinotoxin, heat, acid, anandamide, lipid metabolites, etc., and thus plays a key role in mammals as a molecular integrator of noxious stimuli Sex (Tominaga et al., 1998, Neuron, 21 pp531-543; Hwang et al., 2000, PNAS, 97, pp6155-6160). TRPV1 is primarily expressed in primary afferent sensory neurons, but ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D419/08C07D411/04C07D413/04
CPCC07D213/56C07D213/64C07D213/61C07D213/65A61P25/00A61P29/00
Inventor 金善映金镇官李玘和禹柄英申松锡牟周炫金星日郑然守林庆珉崔镇圭河骏龙高现珠朴永镐徐永钜金熙斗朴亨根吴禹泽
Owner AMOREPACIFIC CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com